Common Contracts
932 similar Underwriting Agreement contracts by Amerant Bancorp Inc., Aquestive Therapeutics, Inc., Arthur J. Gallagher & Co., others
PROCEPT BIOROBOTICS CORPORATION (a Delaware corporation) 1,923,076 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 31st, 2024 • PROCEPT BioRobotics Corp • Surgical & medical instruments & apparatus • New York
ProQR Therapeutics N.V. 18,000,000 Ordinary Shares UNDERWRITING AGREEMENT Dated: October 22, 2024 ProQR Therapeutics N.V. 18,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • October 25th, 2024 • ProQR Therapeutics N.V. • Pharmaceutical preparations • New York
CAPRICOR THERAPEUTICS, INC. (a Delaware corporation) 4,412,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 17th, 2024 • Capricor Therapeutics, Inc. • Pharmaceutical preparations • New York
SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) envveno medical corporationUnderwriting Agreement • September 30th, 2024 • enVVeno Medical Corp • Surgical & medical instruments & apparatus • New York
7,900,000 Shares of Class A Voting Common Stock (Par Value $0.10 per Share) AMERANT BANCORP INC. UNDERWRITING AGREEMENTUnderwriting Agreement • September 27th, 2024 • Amerant Bancorp Inc. • National commercial banks • New York
HAWAIIAN ELECTRIC INDUSTRIES, INC. 54,054,054 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • September 24th, 2024 • Hawaiian Electric Co Inc • Electric services • New York
ASCENDIS PHARMA A/S (a company organized under the laws of Denmark) 2,000,000 American Depositary Shares Representing an Aggregate of 2,000,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • September 23rd, 2024 • Ascendis Pharma a/S • Pharmaceutical preparations • New York
GUARDIAN PHARMACY SERVICES, INC. (a Delaware corporation) [•] Shares of Class A Common Stock, $0.001 par value UNDERWRITING AGREEMENTUnderwriting Agreement • September 16th, 2024 • Guardian Pharmacy Services, Inc. • Retail-drug stores and proprietary stores • New York
REVIVA PHARMACEUTICALS HOLDINGS, INC. 3,276,262 OF SHARES OF COMMON STOCK, PAR VALUE $0.0001 PER SHARE PRE-FUNDED WARRANTS TO PURCHASE 1,485,643 SHARES OF SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE WARRANTS TO PURCHASE 4,761,905 SHARES OF...Underwriting Agreement • August 21st, 2024 • Reviva Pharmaceuticals Holdings, Inc. • Pharmaceutical preparations • New York
MeiraGTx Holdings plc (a Cayman Islands exempted company) 12,500,000 Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • August 13th, 2024 • MeiraGTx Holdings PLC • Biological products, (no disgnostic substances) • New York
MeiraGTx Holdings plc, (a Cayman Islands exempted company) (the “Company”) confirms its agreement with each of the Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA Securities, Inc. is acting as representative (in such capacity, the “Representative”), with respect to the issue and sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of ordinary shares, nominal value $0.00003881 per share, of the Company (“Ordinary Shares”) set forth in Schedule A hereto. The aforesaid 12,500,000 Ordinary Shares to be purchased by the Underwriters are herein called the “Securities.”
ContractUnderwriting Agreement • June 14th, 2024 • J.Jill, Inc. • Women's, misses', and juniors outerwear • New York
TAMBORAN RESOURCES CORPORATION (a Delaware corporation) [•] Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • June 5th, 2024 • Tamboran Resources Corp • Crude petroleum & natural gas • New York
Verisk Analytics, Inc. (a Delaware corporation)Underwriting Agreement • June 5th, 2024 • Verisk Analytics, Inc. • Services-computer processing & data preparation • New York
Verisk Analytics, Inc., a Delaware corporation (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and HSBC Securities (USA) Inc. (“HSBC”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and HSBC are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company, and the purchase by the Underwriters, acting severally and not jointly, of $600,000,000 aggregate principal amount of the Company’s 5.250% Senior Notes due 2034 (the “Securities”). The Securities will be issued pursuant to the Base Indenture, dated as of March 6, 2019 (the “Base Indenture”) between the Company and Computershare Trust Company, N.A. as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee”), as supplemented by a Supplemental Indenture, to be dated as
BRUKER CORPORATION (a Delaware corporation) 6,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 31st, 2024 • Bruker Corp • Laboratory analytical instruments • New York
GAUZY LTD. (a company organized under the laws of the State of Israel) [●] Ordinary Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 29th, 2024 • Gauzy Ltd. • Miscellaneous electrical machinery, equipment & supplies • New York
Perspective Therapeutics, Inc. 51,515,880 Shares of Common Stock Pre-Funded Warrants to Purchase 1,464,252 Shares of Common Stock UNDERWRITING AGREEMENT Dated: May 24, 2024Underwriting Agreement • May 29th, 2024 • Perspective Therapeutics, Inc. • Surgical & medical instruments & apparatus • New York
Perspective Therapeutics, Inc. (the “Company”), confirms its agreement with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA is acting as representative (in such capacity, the “Representative”), with respect to the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares (the “Shares”) of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) and pre-funded warrants to purchase shares of Common Stock at an exercise price equal to $0.001 per share (the “Pre-Funded Warrants”), set forth in Schedules A and B hereto. The shares of Common Stock issuable upon exercise of the Pre-Funded Warrants are hereinafter referred to as the “Warrant Shares.” The aforesaid Shares and Pre-Funded Warrants to be purchased b
NOTICE REGARDING UNDERWRITING AGREEMENTUnderwriting Agreement • May 13th, 2024 • M&t Bank Corp • State commercial banks • New York
The attached Underwriting Agreement is a contractual document that establishes and governs the legal relations among the parties with respect to the transactions described therein. The Underwriting Agreement is not intended to be a source for investors of factual, business, or operational information about the Company. The representations and warranties, covenants and agreements contained in the Underwriting Agreement were made only for purposes of the Underwriting Agreement, were solely for the benefit of the parties to the Underwriting Agreement, and in some cases are subject to limitations agreed among those parties. Accordingly, investors and security holders should not rely on representations or warranties, covenants and agreements as characterizations of the actual state of facts or condition of the Company.
DIGITAL REALTY TRUST, INC. 10,500,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • May 10th, 2024 • Digital Realty Trust, L.P. • Real estate • New York
ATLASSIAN CORPORATION (a Delaware corporation) $500,000,000 5.250% Senior Notes due 2029 $500,000,000 5.500% Senior Notes due 2034 UNDERWRITING AGREEMENT Dated: May 8, 2024 ATLASSIAN CORPORATION (a Delaware corporation) $500,000,000 5.250% Senior...Underwriting Agreement • May 9th, 2024 • Atlassian Corp • Services-prepackaged software • New York
VINCERX PHARMA, INC. (a Delaware corporation) 6,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 16,000,000 Shares of Common Stock Warrants to Purchase 22,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2024 • Vincerx Pharma, Inc. • Pharmaceutical preparations • New York
AZZ INC. (a Texas corporation) 4,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 26th, 2024 • Azz Inc • Coating, engraving & allied services • New York
MONTROSE ENVIRONMENTAL GROUP, INC. (a Delaware corporation) 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 19th, 2024 • Montrose Environmental Group, Inc. • Services-management consulting services • New York
INOVIO PHARMACEUTICALS, INC. (a Delaware corporation) 2,536,258 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 2,135,477 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • April 17th, 2024 • Inovio Pharmaceuticals, Inc. • Surgical & medical instruments & apparatus • New York
CTO Realty Growth, Inc. (a Maryland corporation) 1,500,000 Shares of 6.375% Series A Cumulative Redeemable Preferred Stock UNDERWRITING AGREEMENT Dated: April 4, 2024 CTO Realty Growth, Inc. (a Maryland corporation) 1,500,000 Shares of 6.375% Series A...Underwriting Agreement • April 10th, 2024 • CTO Realty Growth, Inc. • Real estate investment trusts • New York
CTO Realty Growth, Inc., a Maryland corporation (the “Company”), confirms its agreement with Raymond James & Associates, Inc. (“Raymond James”), and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters”), for whom Raymond James is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of 1,500,000 shares of 6.375% Series A Cumulative Redeemable Preferred Stock, liquidation preference $25.00 per share (the “Series A Preferred Stock”), a series of the Company’s preferred stock, $0.01 par value per share (“Preferred Stock”), and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 225,000 additional shares of Series A Preferred Stock to cover over-allotments, pursuant to and in accordance with the terms and conditions
BOWMAN CONSULTING GROUP LTD. (a Delaware corporation) 1,470,588 Shares of Common Stock (par value $0.01) UNDERWRITING AGREEMENTUnderwriting Agreement • April 1st, 2024 • Bowman Consulting Group Ltd. • Services-management consulting services • New York
Bowman Consulting Group Ltd., a Delaware corporation (the “Company”), and the persons listed in Schedule B hereto (the “Selling Stockholders”), confirm their respective agreements with BofA Securities, Inc. (“BofA”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom BofA and Robert W. Baird & Co. Incorporated are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the Selling Stockholders, acting severally and not jointly, and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.01 per share, of the Company (“Common Stock”) set forth in Schedules A and B hereto and (ii) the grant by the Company and the Selling Stockholders to the Underwriters, acting severally and not jointly, of the o
SIRIUSPOINT LTD. 7.000% Senior Notes due 2029 UNDERWRITING AGREEMENTUnderwriting Agreement • March 28th, 2024 • SiriusPoint LTD • Fire, marine & casualty insurance • New York
Final Maturity Date: The “Final Maturity Date” means (1) April 5, 2029 (the “Scheduled Maturity Date”), if, on the Scheduled Maturity Date, the BMA Redemption Requirements (as defined in the preliminary prospectus supplement) are satisfied, or (2) otherwise, following the Scheduled Maturity Date, the earlier of (a) the date falling ten (10) business days after the BMA Redemption Requirements are satisfied and would continue to be satisfied if such payment were made and (b) the date on which a Winding-Up of the Issuer occurs.
FATE THERAPEUTICS, INC. (a Delaware corporation) 14,545,454 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 21st, 2024 • Fate Therapeutics Inc • Biological products, (no disgnostic substances) • New York
UNDERWRITING AGREEMENTUnderwriting Agreement • March 21st, 2024 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • New York
INTAPP, INC. (a Delaware corporation) 7,000,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 7th, 2024 • Intapp, Inc. • Services-prepackaged software • New York
JANUX THERAPEUTICS, INC. (a Delaware corporation) 4,440,851 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,935,483 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 29th, 2024 • Janux Therapeutics, Inc. • Pharmaceutical preparations • New York
CBRE SERVICES, INC. (a Delaware corporation) $500,000,000 5.500% Senior Notes due 2029 UNDERWRITING AGREEMENT Dated: February 20, 2024Underwriting Agreement • February 23rd, 2024 • Cbre Group, Inc. • Real estate • New York
Arthur J. Gallagher & Co. (a Delaware corporation) $500,000,000 5.450% Senior Notes due 2034 $500,000,000 5.750% Senior Notes due 2054 UNDERWRITING AGREEMENTUnderwriting Agreement • February 15th, 2024 • Arthur J. Gallagher & Co. • Insurance agents, brokers & service • New York
MERIDIANLINK, INC. (a Delaware corporation) 6,906,015 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 8th, 2024 • MeridianLink, Inc. • Services-prepackaged software • New York
MeridianLink, Inc., a Delaware corporation (the “Company”), and the persons listed in Schedule B hereto (the “Selling Stockholders”), confirm their respective agreement with Citigroup Global Markets Inc. (“Citi”) and J.P. Morgan Securities LLC (“JPM”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Citi and JPM are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Selling Stockholders, acting severally and not jointly, and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.001 per share, of the Company (“Common Stock”) set forth in Schedules A and B hereto and (ii) the grant by the Selling Stockholders, acting severally and not jointly, to the Underwriters, acting severally and not jointly,
PepGen Inc. (a Delaware corporation) 7,530,000 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • February 7th, 2024 • PepGen Inc. • Pharmaceutical preparations • New York
VAXCYTE, INC. (a Delaware corporation) 10,937,500 Shares of Common Stock and Pre-Funded Warrants to Purchase 781,250 Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • January 31st, 2024 • Vaxcyte, Inc. • Biological products, (no disgnostic substances) • New York
